Как достигается значимое увеличение выживаемости при раке поджелудочной железы. Роль нутритивного статуса и сопроводительной терапии

1. Neoptolemos JP, Kleeff J, Michl P, et al. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333‑48. DOI:10.1038/s41575‑018‑0005‑x
2. Data visualization tools for exploring the global cancer burden in 2020. Available at: https://gco.iarc.fr/today/home. Accessed: 17.10.2023.
3. Состояние онкологической помощи населению России в 2021 году. Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. М: МНИОИ им. П. А. Герцена, 2022 [Sostoianie onkologicheskoi pomoshchi naseleniiu Rossii v 2021 godu. Pod red. AD Kaprinа, VV Starinskogo, AO Shakhzadovoi. Moscow: MNIOI im. P. A. Gertsena, 2022 (in Russian)].
4. Orth M, Metzger P, Gerum S, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019;14(1):141. DOI:10.1186/s13014‑019‑1345‑6
5. Pancreatic cancer statistics – WCRF International. Available at: https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/ Accessed: 17.10.2023.
6. Pancreatic Cancer Facts – Hirshberg Foundation for Pancreatic Cancer Research. Available at: https://pancreatic.org/pancreatic-cancer/pancreatic-cancer-facts/ Accessed: 17.10.2023.
7. GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990‑2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934‑47. DOI:10.1016/S2468‑1253(19)30347‑4
8. Sirri E, Castro FA, Kieschke J, et al. Recent Trends in Survival of Patients With Pancreatic Cancer in Germany and the United States. Pancreas. 2016;45(6):908‑14. DOI:10.1097/MPA.0000000000000588
9. Worni M, Guller U, White RR, et al. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas. 2013;42(7):1157‑63. DOI:10.1097/MPA.0b013e318291fbc5
10. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694‑705. DOI:10.3748/wjg.v22.i44.9694
11. Luo J, Xiao L, Wu C, et al. The incidence and survival rate of population-based pancreatic cancer patients: Shanghai Cancer Registry 2004‑2009. PLoS One. 2013;8(10):e76052. DOI:10.1371/journal.pone.0076052
12. Key Statistics for Pancreatic Neuroendocrine Tumor. Available at: https://www.cancer.net/cancer-types/neuroendocrine-tumor-pancreas/statistics. Accessed: 28.06.2023.
13. Key Statistics for Pancreatic Cancer. American Cancer Society. Available at: https://cancerstatisticscenter.cancer.org/#!/cancer-site/Pancreas Accessed: 16.10.2023.
14. Cancer Facts & Figures 2023. American Cancer Society. Available at: https://www.acsresources.org/uncategorized/american-cancer-society-facts-figures-2023/ Accessed: 15.10.2023.
15. Pancreatic Cancer Action Network. Available at: https://pancan.org/get-involved/advocacy/ Accessed: 15.10.2023.
16. Van der Geest LGM, van Eijck CHJ, Groot Koerkamp B, et al; Dutch Pancreatic Cancer Group. Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. Cancer Med. 2018;7(10):4943‑51. DOI:10.1002/cam4.1750
17. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378(9791):607‑20. DOI:10.1016/S0140‑6736(10)62307‑0
18. Balaban EP, Mangu PB, Khorana AA, et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(22):2654‑68. DOI:10.1200/JCO.2016.67.5561
19. Vaccaro V, Sperduti I, Vari S, et al. Metastatic pancreatic cancer: Is there a light at the end of the tunnel? World J Gastroenterol. 2015;21(16):4788‑801. DOI:10.3748/wjg.v21.i16.4788
20. McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol.  2018;24(43):4846‑61.DOI:10.3748/wjg.v24.i43.4846
21. Latenstein AEJ, van der Geest LGM, Bonsing BA, et al; Dutch Pancreatic Cancer Group. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Eur J Cancer. 2020;125:83‑93. DOI:10.1016/j.ejca.2019.11.002
22. Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995‑2014 (ICBP SURVMARK‑2): a population-based study. Lancet Oncol. 2019;20(11):1493‑505. DOI:10.1016/S1470‑2045(19)30456‑5
23. Nikšić M, Minicozzi P, Weir HK, et al; US CONCORD Working Group. Pancreatic cancer survival trends in the US from 2001 to 2014: a CONCORD‑3 study. Cancer Commun (Lond). 2023;43(1):87‑99. DOI:10.1002/cac2.12375
24. Van Roest MH, van der Aa MA, van der Geest LG, de Jong KP. The Impact of Socioeconomic Status, Surgical Resection and Type of Hospital on Survival in Patients with Pancreatic Cancer. A Population-Based Study in The Netherlands. PLoS One. 2016;11(11):e0166449. DOI:10.1371/journal.pone.0166449
25. Cipora E, Partyka O, Pajewska M, et al. Treatment Costs and Social Burden of Pancreatic Cancer. Cancers (Basel). 2023;15(6):1911. DOI:10.3390/cancers15061911
26. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019;10(1):10‑27. DOI:10.14740/wjon1166
27. Yin MY, Xi LT, Liu L, et al. Pancreatic cancer incidence and mortality patterns in 2006‑2015 and prediction of the epidemiological trend to 2025 in China. World J Clin Cases. 2022;10(14):4404‑13. DOI:10.12998/wjcc.v10.i14.4404
28. Zhao C, Gao F, Li Q, et al. The Distributional Characteristic and Growing Trend of Pancreatic Cancer in China. Pancreas. 2019;48(3):309‑14. DOI:10.1097/MPA.0000000000001222
29. Ilic I, Ilic M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis. World J Gastroenterol. 2022;28(32):4698‑715. DOI:10.3748/wjg.v28.i32.4698
30. Mukherji R, Debnath D, Hartley ML, Noel MS. The Role of Immunotherapy in Pancreatic Cancer. Curr Oncol. 2022;29(10):6864‑92. DOI:10.3390/curroncol29100541
31. Leroux C, Konstantinidou G. Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. Cancers (Basel). 2021;13(4):799. DOI:10.3390/cancers13040799
32. Tuli R, David J, Lobaugh S, et al. Duration of therapy for locally advanced pancreatic cancer: Does it matter? Cancer Med. 2020;9(13):4572‑80. DOI:10.1002/cam4.3081
33. Truty MJ, Kendrick ML, et al. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Ann Surg. 2021;273(2):341‑9. DOI:10.1097/SLA.0000000000003284
34. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma. Version 2.2023. NCCN Clinical Practice Guidelines in Oncology. DOI:10.6004/jnccn.2021.0017.
35. Vujasinovic M, Valente R, Del Chiaro M, et al. Pancreatic Exocrine Insufficiency in Pancreatic Cancer. Nutrients. 2017;9(3):183. DOI:10.3390/nu9030183
36 Capurso G, Traini M, Piciucchi M, et al. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol. 2019;12:129‑39. DOI:10.2147/CEG.S168266
37. Roeyen G, Berrevoet F, Borbath I, et al. Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer. ESMO Open. 2022;7(1):100386. DOI:10.1016/j.esmoop.2022.100386
38. Torphy RJ, Fujiwara Y, Schulick RD. Pancreatic cancer treatment: better, but a long way to go. Surg Today. 2020;50(10):1117‑25. DOI:10.1007/s00595‑020‑02028‑0
39. Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. J Invest Surg. 2023;36(1):2129884. DOI:10.1080/08941939.2022.2129884
40. Рак поджелудочной железы. Клинические рекомендации. 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/355_4. Ссылка активна на 21.04.2023 [Rak podzheludochnoi zhelezy. Klinicheskie rekomendatsii. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/355_4. Accessed: 21.04.2023 (in Russian)].
41. Barkin JA, Westermann A, Hoos W, et al. Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy and Symptomatic Response in Pancreatic Cancer Patients. Pancreas. 2019;48(6):780‑6. DOI:10.1097/MPA.0000000000001330
42. Diéguez-Castillo C, Jiménez-Luna C, Prados J, et al. State of the Art in Exocrine Pancreatic Insufficiency. Medicina (Kaunas). 2020;56(10):523. DOI:10.3390/medicina56100523
43. Halloran CM, Cox TF, Chauhan S, et al. Partial pancreatic resection for pancreatic malignancy is associated with sustained pancreatic exocrine failure and reduced quality of life: a prospective study. Pancreatology. 2011;11(6):535‑45. DOI:10.1159/000333308
44. Frulloni L, Falconi M, Gabbrielli A, et al. Italian consensus guidelines for chronic pancreatitis. Dig Liver Dis. 2010;42(Suppl. 6):S381‑406. DOI:10.1016/S1590‑8658(10)60682‑2
45. Dominguez-Muñoz JE. Diagnosis and treatment of pancreatic exocrine insufficiency. Curr Opin Gastroenterol. 2018;34(5):349‑54. DOI:10.1097/MOG.0000000000000459
46. Маев И.В., Кучерявый Ю. А., Андреев Д. Н. Экзокринная недостаточность поджелудочной железы: клиническое значение и подходы к коррекции с позиций доказательной медицины. Терапевтический архив. 2021;93(4):509‑15 [Maev IV, Kucheryavyy YA, Andreev DN. Exocrine pancreas insufficiency: clinical significance and approaches to correction from evidence medicine. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(4):509‑15 (in Russian)]. DOI:10.26442/00403660.2021.04.200800
47. Ивашкин В.Т., Маев И. В., Охлобыстин А. В., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению экзокринной недостаточности поджелудочной железы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(2):54‑80 [Ivashkin VT, Mayev IV, Okhlobystin AV, et al. Diagnostics and treatment of exocrine pancreatic insufficiency: clinical guidelines of the Russian gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(2):54‑80 (in Russian)].
48. Шестакова М.В., Маев И. В., Аметов А. С., и др. Экзокринная недостаточность поджелудочной железы при сахарном диабете 1 и 2 типа. Сахарный диабет. 2023;26(2):215‑24 [Shestakova MV, Maev IV, Ametov AS, et al. Pancreatic exocrine insufficiency in diabetes mellitus. Diabetes Mellitus. 2023;26(2):215‑24 (in Russian)]. DOI:10.14341/DM13027
49. Lekkerkerker SJ, Hoogenboom SA, de Koning FH, et al. Correlation Between the Standard Pancreatic Elastase‑1 Enzyme-Linked Immunosorbent Assay Test and the New, Rapid Fecal Pancreatic Elastase‑1 Test for Diagnosing Exocrine Pancreatic Insufficiency. Pancreas. 2019;48(4):e26‑7. DOI:10.1097/MPA.0000000000001291
50. Khatkov IE, Maev IV, Abdulkhalov SR, et al; Pancreatic Club Russia PMS. Russian Consensus on Exo- and Endocrine Pancreatic Insufficiency After Surgical Treatment. Turk J Gastroenterol. 2021;32(3):225‑39. DOI:10.5152/tjg.2021.20445
51. Покатаев И.А., Гладков О. А., Загайнов В. Е., и др. Практические рекомендации по лекарственному лечению рака поджелудочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2021;11(3S2‑1):468‑82 [Pokataev IA, Gladkov OA, Zagainov VE, et al. Practical recommendations for the medical treatment of pancreatic cancer. Malignant Tumours: Russian Society Of Clinical Oncology. 2021;11(3S2‑1):468‑82 (in Russian)]. DOI:10.18027/2224‑5057‑2021‑11‑3s2‑27
52. Bartel MJ, Asbun H, Stauffer J, Raimondo M. Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature. Dig Liver Dis. 2015;47(12):1013‑20. DOI:10.1016/j.dld.2015.06.015
53. Reni M, Zanon S, Balzano G, et al. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur J Cancer. 2018;102:95‑102. DOI:10.1016/j.ejca.2018.07.007
54. Giordano G, Cincione RI, Losavio F, et al. Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer. Oncologist. 2023;28(9):e793‑800. DOI:10.1093/oncolo/oyad101
55. Bruno MJ, Haverkort EB, Tijssen GP, et al. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut. 1998;42(1):92‑6. DOI:10.1136/gut.42.1.92
56. Trestini I, Carbognin L, Peretti U, et al. Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma. Front Oncol. 2021;11:688889. DOI:10.3389/fonc.2021.688889
57. Keller J, Layer P. Human pancreatic exocrine response to nutrients in health and disease. Gut. 2005;54(Suppl. 6):1‑28. DOI:10.1136/gut.2005.065946
58. Löhr JM, Dominguez-Munoz E, Rosendahl J, et al; HaPanEU/UEG Working Group. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J. 2017;5(2):153‑99. DOI:10.1177/2050640616684695
59. Domínguez-Muñoz JE. Pancreatic enzyme replacement therapy: exocrine pancreatic insufficiency after gastrointestinal surgery. HPB (Oxford). 2009;11(Suppl. 3):3‑6. DOI:10.1111/j.1477‑2574.2009.00132.x
60. De-Madaria E, Abad-González A, Aparicio JR, et al. The Spanish Pancreatic Club’s recommendations for the diagnosis and treatment of chronic pancreatitis: part 2 (treatment). Pancreatology. 2013;13(1):18‑28. DOI:10.1016/j.pan.2012.11.310
61. PERT Guide for health professionals. Available at:  https://www.pancreaticcancer.org.uk/wp-content/uploads/2021/05/PERT-Guide-for-health-professionals-M.... Accessed: 15.10.2023.
62. Phillips ME, Hopper AD, Leeds JS, et al. Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines. BMJ Open Gastroenterol. 2021;8(1): e000643. DOI:10.1136/bmjgast‑2021‑000643
63. Рекомендации по поддерживающей и сопроводительной терапии RUSSCO. Режим доступа: https://rosoncoweb.ru/standarts/suptherapy/ Ссылка активна на 14.10.2023 [Rekomendatsii po podderzhivaiushchei i soprovoditel’noi terapii RUSSCO. Available at: https://rosoncoweb.ru/standarts/suptherapy/ Accessed: 14.10.2023 (in Russian)].
64. Протоколы клинических рекомендаций Общества специалистов поддерживающей терапии в онкологии (RASSC). 2023. Режим доступа: https://rassc.org/ru/recommendations. Ссылка активна на 14.10.2023 [Protokoly klinicheskikh rekomendatsii Obshchestva spetsialistov podderzhivaiushchei terapii v onkologii (RASSC). 2023. Available at: https://rassc.org/ru/recommendations. Accessed: 14.10.2023 (in Russian)].
65. Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 2018;18(1):688. DOI:10.1186/s12885‑018‑4610‑4
66. Практические рекомендации по лечению рака поджелудочной железы Российского общества клинической онкологии (RUSSCO). 2021. Режим доступа: https://www.rosoncoweb.ru/standarts/RUSSCO/2021/ Ссылка активна на 05.10.2023 [Prakticheskie rekomendatsii po lecheniiu raka podzheludochnoi zhelezy Rossiiskogo obshchestva klinicheskoi onkologii (RUSSCO). 2021. Available at: https://www.rosoncoweb.ru/standarts/RUSSCO/2021/ Accessed: 05.10.2023 (in Russian)].
67. Conroy T, Desseigne F, Ychou M, et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817‑25. DOI:10.1056/NEJMoa1011923
68. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691‑703. DOI:10.1056/NEJMoa1304369
69. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403‑13. DOI:10.1200/JCO.1997.15.6.2403
70. Sell NM, Lee GC, Fernández-Del Castillo C, et al. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Pancreas. 2020;49(7):897‑903. DOI:10.1097/MPA.0000000000001590
71. Chuong MD, Frakes JM, Figura N, et al. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. J Gastrointest Oncol. 2016;7(2):221‑7. DOI:10.3978/j.issn.2078‑6891.2015.075
72. Blair AB, Yin LD, Pu N, et al. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Ann Surg. 2021;274(1):162‑9. DOI:10.1097/SLA.0000000000003570
73. Fietkau R, Grützmann R, Wittel UA, et al. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO‑007± trial. Strahlenther Onkol. 2021;197(1):8‑18. DOI:10.1007/s00066‑020‑01680‑2
74. Andreou A, Knitter S, Klein F, et al. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Surg Oncol. 2018;27(4):688‑94. DOI:10.1016/j.suronc.2018.09.004
75. Dusch N, Weiss C, Ströbel P, et al. Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg. 2014;18(4):674‑81. DOI:10.1007/s11605‑013‑2408‑x
76. Zhou W, Wang D, Lou W. Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis. Cancer Control. 2020;27(1):1073274820976593. DOI:10.1177/1073274820976593
77. Sakaguchi T, Valente R, Tanaka K, et al. Surgical treatment of metastatic pancreatic ductal adenocarcinoma: A review of current literature. Pancreatology. 2019;19(5):672‑80. DOI:10.1016/j.pan.2019.05.466
78. Yamada S, Fujii T, Yamamoto T, et al. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. J Gastrointest Oncol. 2021;12(Suppl. 1):S110‑7. DOI:10.21037/jgo‑20‑243
79. Wei M, Shi S, Hua J, et al; Chinese Study Group for Pancreatic Cancer (CSPAC). Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC‑1). BMJ Open. 2019;9(12):e033452. DOI:10.1136/bmjopen‑2019‑033452
80. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27(11):1806‑13. DOI:10.1200/JCO.2008.17.7188
81. Kamisawa T, Isawa T, Koike M, et al. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas. 1995;11(4):345‑9. DOI:10.1097/00006676‑199511000‑00005
82. Mao C, Domenico DR, Kim K, et al. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg. 1995;130(2):125‑34. DOI:10.1001/archsurg.1995.01430020015001
83. Peixoto RD, Speers C, McGahan CE, et al. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med. 2015;4(8):1171‑7. DOI:10.1002/cam4.459
84. NCCN Guidelines. Pancreatic Adenocarcinoma. 2018. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455. Accessed: 05.10.2023.
85. Fortner JG. Regional resection of cancer of the pancreas: a new surgical approach. Surgery. 1973;73(2):307‑20.
86. Tee MC, Krajewski AC, Groeschl RT, et al. Indications and Perioperative Outcomes for Pancreatectomy with Arterial Resection. J Am Coll Surg. 2018;227(2):255‑69. DOI:10.1016/j.jamcollsurg.2018.05.001
87. Boggi U. Resection for pancreatic cancer with arterial involvement: A paradigm shift away from unresectable to „how to do it“. Surgery. 2021;169(5):1036. DOI:10.1016/j.surg.2020.10.047
88. Loos M, Kester T, Klaiber U, et al. Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve. Ann Surg. 2022;275(4):759‑68. DOI:10.1097/SLA.0000000000004054
89. Практические рекомендации по лечению рака поджелудочной железы Российского общества клинической онкологии (RUSSCO). 2023. Режим доступа: https://www.rosoncoweb.ru/standarts/RUSSCO/2023/ Ссылка активна на 05.10.2023 [Prakticheskie rekomendatsii po lecheniiu raka podzheludochnoi zhelezy Rossiiskogo obshchestva klinicheskoi onkologii (RUSSCO). 2023. Available at: https://www.rosoncoweb.ru/standarts/RUSSCO/2023/ Accessed: 05.10.2023 (in Russian)].
90. Diener MK, Mihaljevic AL, Strobel O, et al. Periarterial divestment in pancreatic cancer surgery. Surgery. 2021;169(5):1019‑25. DOI:10.1016/j.surg.2020.08.030
91. Bachellier P, Addeo P, Faitot F, et al. Pancreatectomy With Arterial Resection for Pancreatic Adenocarcinoma: How Can It Be Done Safely and With Which Outcomes?: A Single Institution’s Experience With 118 Patients. Ann Surg. 2020;271(5):932‑40. DOI:10.1097/SLA.0000000000003010
92. Egorov V, Kim P, Kharazov A, et al. Hemodynamic, Surgical and Oncological Outcomes of 40 Distal Pancreatectomies with Celiac and Left Gastric Arteries Resection (DP CAR) without Arterial Reconstructions and Preoperative Embolization. Cancers (Basel). 2022;14(5):1254. DOI:10.3390/cancers14051254
93. Stoop TF, Ateeb Z, Ghorbani P, et al. Impact of Endocrine and Exocrine Insufficiency on Quality of Life After Total Pancreatectomy. Ann Surg Oncol. 2020;27(2):587‑96. DOI:10.1245/s10434‑019‑07853‑3
94. Wu W, Dodson R, Makary MA, et al. A Contemporary Evaluation of the Cause of Death and Long-Term Quality of Life After Total Pancreatectomy. World J Surg. 2016;40(10):2513‑8. DOI:10.1007/s00268‑016‑3552‑8
95. Téoule P, Tombers K, Rahbari M, et al. Definition und Behandlung der A.-mesenterica-superior-Revaskularisations- und -Dissektions-assoziierten Diarrhö (SMARD-Syndrom) in Deutschland [Definition and treatment of superior mesenteric artery revascularization and dissection-associated diarrhea (SMARD syndrome) (in German)]. Chirurg. 2022;93(2):173‑81. DOI:10.1007/s00104‑021‑01427‑4
96. Sabater L, Ausania F, Bakker OJ, et al. Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery. Ann Surg. 2016;264(6):949‑58. DOI:10.1097/SLA.0000000000001732
97. Roberts KJ, Schrem H, Hodson J, et al. Pancreas exocrine replacement therapy is associated with increased survival following pancreatoduodenectomy for periampullary malignancy. HPB (Oxford). 2017;19(10):859‑67. DOI:10.1016/j.hpb.2017.05.009
98. Kindler HL, Hammel P, Reni M, et al. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022;40(34):3929‑39. DOI:10.1200/JCO.21.01604
99. O’Reilly EM, Melisi D, Macarulla T, et al. Liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18‑month survival rates from the phase 3 NAPOLI 3 trial. J Clin Oncol. 2023;41(Suppl. 16):4006. DOI:10.1200/JCO.2023.41.16_suppl.4006
100. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317‑27. DOI:10.1056/NEJMoa1903387
101. Carrato A, Vieitez JM, Benavides M, et al; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results. Eur J Cancer. 2020;139:51‑8. DOI:10.1016/j.ejca.2020.07.035
102. Neoptolemos JP, Palmer DH, Ghaneh P, et al; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC‑4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011‑24. DOI:10.1016/S0140‑6736(16)32409‑6
103. Conroy T, Hammel P, Hebbar M, et al; Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395‑406. DOI:10.1056/NEJMoa1809775
104. Lee W, Yoon YS, Han HS, et al. Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. World J Surg. 2017;41(2):562‑73. DOI:10.1007/s00268‑016‑3798‑1
105. Cunningham D, Allum WH, Stenning SP, et al; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11‑20. DOI:10.1056/NEJMoa055531
106. Sauer R, Becker H, Hohenberger W, et al; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731‑40. DOI:10.1056/NEJMoa040694
107. Yamada S, Fujii T, Sugimoto H, et al. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas. 2013;42(6):1004‑10. DOI:10.1097/MPA.0b013e31827b2d7c
108. Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018;4(7):963‑69. DOI:10.1001/jamaoncol.2018.0329
109. Wei AC, Ou FS, Shi Q, et al. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019;26(13):4489‑97. DOI:10.1245/s10434‑019‑07685‑1
110. Barbour AP, Samra JS, Haghighi KS, et al; Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators. The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. Ann Surg Oncol. 2020;27(7):2506‑15. DOI:10.1245/s10434‑020‑08205‑2
111. Sohal D, Duong MT, Ahmad SA, et al. SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). J Clin Oncol. 2020;38(Suppl. 15):4504. DOI:10.1200/JCO.2020.38.15_suppl.4504
112. Lutfi W, Talamonti MS, Kantor O, et al. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. Surgery. 2016;160(3):714‑24. DOI:10.1016/j.surg.2016.05.029
113. Versteijne E, Vogel JA, Besselink MG, et al; Dutch Pancreatic Cancer Group. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946‑58. DOI:10.1002/bjs.10870
114. NCCN Guidelines. Pancreatic Adenocarcinoma. Version 2.2022. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455. Accessed: 21.04.2023.
115. Saito T, Nakai Y, Isayama H, et al. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Pancreas. 2018;47(7):800‑6. DOI:10.1097/MPA.0000000000001079
116. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‑fluorouracil), and high dose radiation + 5‑fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981;48(8):1705‑10. DOI:10.1002/1097‑0142(19811015)48:8<1705:: aid-cncr2820480803>3.0.co;2‑4
117. Group G.T.S. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst. 1988;80(10):751‑5. PMID: 2898536
118. Evans DB, Wolff RA, Hess KR. Adjuvant radiotherapy and 5‑fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 2000;232(5):727. DOI:10.1097/00000658‑200011000‑00028
119. Hammel P, Huguet F, van Laethem JL, et al; LAP07 Trial Group. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844‑53. DOI:10.1001/jama.2016.4324
120. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14(4):317‑26. DOI:10.1016/S1470‑2045(13)70021‑4
121. Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105‑12. DOI:10.1200/JCO.2011.34.8904
122. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000‑01 FFCD/SFRO study. Ann Oncol. 2008;19(9):1592‑9. DOI:10.1093/annonc/mdn281
123. Ren F, Li S, Zhang Y, et al. Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis. Radiat Oncol. 2019;14(1):84. DOI:10.1186/s13014‑019‑1294‑0
124. Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76(1):48‑53. DOI:10.1016/j.radonc.2004.12.022
125. Pollom EL, Alagappan M, von Eyben R, et al. Single-versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Int J Radiat Oncol Biol Phys. 2014;90(4):918‑25. DOI:10.1016/j.ijrobp.2014.06.066
126. Hammer HF. Pancreatic exocrine insufficiency: diagnostic evaluation and replacement therapy with pancreatic enzymes. Dig Dis. 2010;28(2):339‑43. DOI:10.1159/000319411
127. Хронический панкреатит. Клинические рекомендации. Общероссийская общественная организация «Российское общество хирургов», Российская гастроэнтерологическая ассоциация, Международная общественная организация «Ассоциация хирургов-гепатологов», Ассоциация «Эндоскопическое общество “РЭндО”». 2020. Режим доступа: https://cr.minzdrav.gov.ru/schema/273_4. 2020. Ссылка активна на 15.09.2023 [Khronicheskii pankreatit. Klinicheskie rekomendatsii. Obshcherossiiskaia obshchestvennaia organizatsiia «Rossiiskoe obshchestvo khirurgov», Rossiiskaia gastroenterologicheskaia assotsiatsiia, Mezhdunarodnaia obshchestvennaia organizatsiia «Assotsiatsiia khirurgov-gepatologov», Assotsiatsiia «Endoskopicheskoe obshchestvo “REndO”». 2020. Available at: https://cr.minzdrav.gov.ru/schema/273_4. 2020. Accessed: 15.09.2023 (in Russian)].
128. Shimizu K, Ito T, Irisawa A, et al. Evidence-based clinical practice guidelines for chronic pancreatitis 2021. J Gastroenterol. 2022;57(10):709‑24. DOI:10.1007/s00535‑022‑01911‑6
129. Working Party of the Australasian Pancreatic Club; Smith RC, Smith SF, Wilson J, et al. Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency. Pancreatology. 2016;16(2):164‑80. DOI:10.1016/j.pan.2015.12.006
130. Кистозный фиброз (муковисцидоз). Клинические рекомендации. Союз педиатров России, Ассоциация медицинских генетиков, Российское респираторное общество, Российское трансплантологическое общество, Ассоциация детских врачей Московской области. 2021. Режим доступа: https://cr.minzdrav.gov.ru/schema/372_2. 2021. Ссылка активна на 15.09.2023 [Kistoznyi fibroz (mukovistsidoz). Klinicheskie rekomendatsii. Soiuz pediatrov Rossii, Assotsiatsiia meditsinskikh genetikov, Rossiiskoe respiratornoe obshchestvo, Rossiiskoe transplantologicheskoe obshchestvo, Assotsiatsiia detskikh vrachei Moskovskoi oblasti. 2021. Rezhim dostupa: https://cr.minzdrav.gov.ru/schema/372_2. 2021. Available at: https://cr.minzdrav.gov.ru/schema/372_2. 2021. Accessed: 15.09.2023 (in Russian)].

________________________________________________

1. Neoptolemos JP, Kleeff J, Michl P, et al. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333‑48. DOI:10.1038/s41575‑018‑0005‑x
2. Data visualization tools for exploring the global cancer burden in 2020. Available at: https://gco.iarc.fr/today/home. Accessed: 17.10.2023.
3. Sostoianie onkologicheskoi pomoshchi naseleniiu Rossii v 2021 godu. Pod red. AD Kaprinа, VV Starinskogo, AO Shakhzadovoi. Moscow: MNIOI im. P. A. Gertsena, 2022 (in Russian).
4. Orth M, Metzger P, Gerum S, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019;14(1):141. DOI:10.1186/s13014‑019‑1345‑6
5. Pancreatic cancer statistics – WCRF International. Available at: https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/ Accessed: 17.10.2023.
6. Pancreatic Cancer Facts – Hirshberg Foundation for Pancreatic Cancer Research. Available at: https://pancreatic.org/pancreatic-cancer/pancreatic-cancer-facts/ Accessed: 17.10.2023.
7. GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990‑2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934‑47. DOI:10.1016/S2468‑1253(19)30347‑4
8. Sirri E, Castro FA, Kieschke J, et al. Recent Trends in Survival of Patients With Pancreatic Cancer in Germany and the United States. Pancreas. 2016;45(6):908‑14. DOI:10.1097/MPA.0000000000000588
9. Worni M, Guller U, White RR, et al. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas. 2013;42(7):1157‑63. DOI:10.1097/MPA.0b013e318291fbc5
10. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694‑705. DOI:10.3748/wjg.v22.i44.9694
11. Luo J, Xiao L, Wu C, et al. The incidence and survival rate of population-based pancreatic cancer patients: Shanghai Cancer Registry 2004‑2009. PLoS One. 2013;8(10):e76052. DOI:10.1371/journal.pone.0076052
12. Key Statistics for Pancreatic Neuroendocrine Tumor. Available at: https://www.cancer.net/cancer-types/neuroendocrine-tumor-pancreas/statistics. Accessed: 28.06.2023.
13. Key Statistics for Pancreatic Cancer. American Cancer Society. Available at: https://cancerstatisticscenter.cancer.org/#!/cancer-site/Pancreas Accessed: 16.10.2023.
14. Cancer Facts & Figures 2023. American Cancer Society. Available at: https://www.acsresources.org/uncategorized/american-cancer-society-facts-figures-2023/ Accessed: 15.10.2023.
15. Pancreatic Cancer Action Network. Available at: https://pancan.org/get-involved/advocacy/ Accessed: 15.10.2023.
16. Van der Geest LGM, van Eijck CHJ, Groot Koerkamp B, et al; Dutch Pancreatic Cancer Group. Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. Cancer Med. 2018;7(10):4943‑51. DOI:10.1002/cam4.1750
17. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378(9791):607‑20. DOI:10.1016/S0140‑6736(10)62307‑0
18. Balaban EP, Mangu PB, Khorana AA, et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(22):2654‑68. DOI:10.1200/JCO.2016.67.5561
19. Vaccaro V, Sperduti I, Vari S, et al. Metastatic pancreatic cancer: Is there a light at the end of the tunnel? World J Gastroenterol. 2015;21(16):4788‑801. 
DOI:10.3748/wjg.v21.i16.4788
20. McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846‑61. DOI:10.3748/wjg.v24.i43.4846
21. Latenstein AEJ, van der Geest LGM, Bonsing BA, et al; Dutch Pancreatic Cancer Group. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Eur J Cancer. 2020;125:83‑93. DOI:10.1016/j.ejca.2019.11.002
22. Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995‑2014 (ICBP SURVMARK‑2): a population-based study. Lancet Oncol. 2019;20(11):1493‑505. DOI:10.1016/S1470‑2045(19)30456‑5
23. Nikšić M, Minicozzi P, Weir HK, et al; US CONCORD Working Group. Pancreatic cancer survival trends in the US from 2001 to 2014: a CONCORD‑3 study. Cancer Commun (Lond). 2023;43(1):87‑99. DOI:10.1002/cac2.12375
24. Van Roest MH, van der Aa MA, van der Geest LG, de Jong KP. The Impact of Socioeconomic Status, Surgical Resection and Type of Hospital on Survival in Patients with Pancreatic Cancer. A Population-Based Study in The Netherlands. PLoS One. 2016;11(11):e0166449. DOI:10.1371/journal.pone.0166449
25. Cipora E, Partyka O, Pajewska M, et al. Treatment Costs and Social Burden of Pancreatic Cancer. Cancers (Basel). 2023;15(6):1911.
DOI:10.3390/cancers15061911
26. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019;10(1):10‑27. DOI:10.14740/wjon1166
27. Yin MY, Xi LT, Liu L, et al. Pancreatic cancer incidence and mortality patterns in 2006‑2015 and prediction of the epidemiological trend to 2025 in China. World J Clin Cases. 2022;10(14):4404‑13. DOI:10.12998/wjcc.v10.i14.4404
28. Zhao C, Gao F, Li Q, et al. The Distributional Characteristic and Growing Trend of Pancreatic Cancer in China. Pancreas. 2019;48(3):309‑14. 
DOI:10.1097/MPA.0000000000001222
29. Ilic I, Ilic M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis. World J Gastroenterol. 2022;28(32):4698‑715. DOI:10.3748/wjg.v28.i32.4698
30. Mukherji R, Debnath D, Hartley ML, Noel MS. The Role of Immunotherapy in Pancreatic Cancer. Curr Oncol. 2022;29(10):6864‑92. 
DOI:10.3390/curroncol29100541
31. Leroux C, Konstantinidou G. Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. Cancers (Basel). 2021;13(4):799. DOI:10.3390/cancers13040799
32. Tuli R, David J, Lobaugh S, et al. Duration of therapy for locally advanced pancreatic cancer: Does it matter? Cancer Med. 2020;9(13):4572‑80. DOI:10.1002/cam4.3081
33. Truty MJ, Kendrick ML, et al. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Ann Surg. 2021;273(2):341‑9. DOI:10.1097/SLA.0000000000003284
34. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma. Version 2.2023. NCCN Clinical Practice Guidelines in Oncology. DOI:10.6004/jnccn.2021.0017.
35. Vujasinovic M, Valente R, Del Chiaro M, et al. Pancreatic Exocrine Insufficiency in Pancreatic Cancer. Nutrients. 2017;9(3):183. DOI:10.3390/nu9030183
36 Capurso G, Traini M, Piciucchi M, et al. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol. 2019;12:129‑39. DOI:10.2147/CEG.S168266
37. Roeyen G, Berrevoet F, Borbath I, et al. Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer. ESMO Open. 2022;7(1):100386. DOI:10.1016/j.esmoop.2022.100386
38. Torphy RJ, Fujiwara Y, Schulick RD. Pancreatic cancer treatment: better, but a long way to go. Surg Today. 2020;50(10):1117‑25. DOI:10.1007/s00595‑020‑02028‑0
39. Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. J Invest Surg. 2023;36(1):2129884. DOI:10.1080/08941939.2022.2129884
40. Rak podzheludochnoi zhelezy. Klinicheskie rekomendatsii. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/355_4. Accessed: 21.04.2023 (in Russian).
41. Barkin JA, Westermann A, Hoos W, et al. Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy and Symptomatic Response in Pancreatic Cancer Patients. Pancreas. 2019;48(6):780‑6. DOI:10.1097/MPA.0000000000001330
42. Diéguez-Castillo C, Jiménez-Luna C, Prados J, et al. State of the Art in Exocrine Pancreatic Insufficiency. Medicina (Kaunas). 2020;56(10):523. DOI:10.3390/medicina56100523
43. Halloran CM, Cox TF, Chauhan S, et al. Partial pancreatic resection for pancreatic malignancy is associated with sustained pancreatic exocrine failure and reduced quality of life: a prospective study. Pancreatology. 2011;11(6):535‑45. DOI:10.1159/000333308
44. Frulloni L, Falconi M, Gabbrielli A, et al. Italian consensus guidelines for chronic pancreatitis. Dig Liver Dis. 2010;42(Suppl. 6):S381‑406. DOI:10.1016/S1590‑8658(10)60682‑2
45. Dominguez-Muñoz JE. Diagnosis and treatment of pancreatic exocrine insufficiency. Curr Opin Gastroenterol. 2018;34(5):349‑54. DOI:10.1097/MOG.0000000000000459
46. Maev IV, Kucheryavyy YA, Andreev DN. Exocrine pancreas insufficiency: clinical significance and approaches to correction from evidence medicine. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(4):509‑15 (in Russian). DOI:10.26442/00403660.2021.04.200800
47. Ivashkin VT, Mayev IV, Okhlobystin AV, et al. Diagnostics and treatment of exocrine pancreatic insufficiency: clinical guidelines of the Russian gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(2):54‑80 (in Russian).
48. Shestakova MV, Maev IV, Ametov AS, et al. Pancreatic exocrine insufficiency in diabetes mellitus. Diabetes Mellitus. 2023;26(2):215‑24 (in Russian). DOI:10.14341/DM13027
49. Lekkerkerker SJ, Hoogenboom SA, de Koning FH, et al. Correlation Between the Standard Pancreatic Elastase‑1 Enzyme-Linked Immunosorbent Assay Test and the New, Rapid Fecal Pancreatic Elastase‑1 Test for Diagnosing Exocrine Pancreatic Insufficiency. Pancreas. 2019;48(4):e26‑7. DOI:10.1097/MPA.0000000000001291
50. Khatkov IE, Maev IV, Abdulkhalov SR, et al; Pancreatic Club Russia PMS. Russian Consensus on Exo- and Endocrine Pancreatic Insufficiency After Surgical Treatment. Turk J Gastroenterol. 2021;32(3):225‑39. DOI:10.5152/tjg.2021.20445
51. Pokataev IA, Gladkov OA, Zagainov VE, et al. Practical recommendations for the medical treatment of pancreatic cancer. Malignant Tumours: Russian Society Of Clinical Oncology. 2021;11(3S2‑1):468‑82 (in Russian). DOI:10.18027/2224‑5057‑2021‑11‑3s2‑27
52. Bartel MJ, Asbun H, Stauffer J, Raimondo M. Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature. Dig Liver Dis. 2015;47(12):1013‑20. DOI:10.1016/j.dld.2015.06.015
53. Reni M, Zanon S, Balzano G, et al. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur J Cancer. 2018;102:95‑102. DOI:10.1016/j.ejca.2018.07.007
54. Giordano G, Cincione RI, Losavio F, et al. Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer. Oncologist. 2023;28(9):e793‑800. 
DOI:10.1093/oncolo/oyad101
55. Bruno MJ, Haverkort EB, Tijssen GP, et al. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut. 1998;42(1):92‑6. DOI:10.1136/gut.42.1.92
56. Trestini I, Carbognin L, Peretti U, et al. Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma. Front Oncol. 2021;11:688889. DOI:10.3389/fonc.2021.688889
57. Keller J, Layer P. Human pancreatic exocrine response to nutrients in health and disease. Gut. 2005;54(Suppl. 6):1‑28. DOI:10.1136/gut.2005.065946
58. Löhr JM, Dominguez-Munoz E, Rosendahl J, et al; HaPanEU/UEG Working Group. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J. 2017;5(2):153‑99. DOI:10.1177/2050640616684695
59. Domínguez-Muñoz JE. Pancreatic enzyme replacement therapy: exocrine pancreatic insufficiency after gastrointestinal surgery. HPB (Oxford). 2009;11(Suppl. 3):3‑6. DOI:10.1111/j.1477‑2574.2009.00132.x
60. De-Madaria E, Abad-González A, Aparicio JR, et al. The Spanish Pancreatic Club’s recommendations for the diagnosis and treatment of chronic pancreatitis: part 2 (treatment). Pancreatology. 2013;13(1):18‑28. DOI:10.1016/j.pan.2012.11.310
61. PERT Guide for health professionals. Available at:  https://www.pancreaticcancer.org.uk/wp-content/uploads/2021/05/PERT-Guide-for-health-professionals-M.... Accessed: 15.10.2023.
62. Phillips ME, Hopper AD, Leeds JS, et al. Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines. BMJ Open Gastroenterol. 2021;8(1): e000643. DOI:10.1136/bmjgast‑2021‑000643
63. Rekomendatsii po podderzhivaiushchei i soprovoditel’noi terapii RUSSCO. Available at: https://rosoncoweb.ru/standarts/suptherapy/ Accessed: 14.10.2023 (in Russian).
64. Protokoly klinicheskikh rekomendatsii Obshchestva spetsialistov podderzhivaiushchei terapii v onkologii (RASSC). 2023. Available at: https://rassc.org/ru/recommendations. Accessed: 14.10.2023 (in Russian).
65. Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 2018;18(1):688. DOI:10.1186/s12885‑018‑4610‑4
66. Prakticheskie rekomendatsii po lecheniiu raka podzheludochnoi zhelezy Rossiiskogo obshchestva klinicheskoi onkologii (RUSSCO). 2021. Available at: https://www.rosoncoweb.ru/standarts/RUSSCO/2021/ Accessed: 05.10.2023 (in Russian).
67. Conroy T, Desseigne F, Ychou M, et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817‑25. DOI:10.1056/NEJMoa1011923
68. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691‑703. DOI:10.1056/NEJMoa1304369
69. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403‑13. DOI:10.1200/JCO.1997.15.6.2403
70. Sell NM, Lee GC, Fernández-Del Castillo C, et al. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Pancreas. 2020;49(7):897‑903. DOI:10.1097/MPA.0000000000001590
71. Chuong MD, Frakes JM, Figura N, et al. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. J Gastrointest Oncol. 2016;7(2):221‑7. DOI:10.3978/j.issn.2078‑6891.2015.075
72. Blair AB, Yin LD, Pu N, et al. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Ann Surg. 2021;274(1):162‑9. DOI:10.1097/SLA.0000000000003570
73. Fietkau R, Grützmann R, Wittel UA, et al. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO‑007± trial. Strahlenther Onkol. 2021;197(1):8‑18. DOI:10.1007/s00066‑020‑01680‑2
74. Andreou A, Knitter S, Klein F, et al. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Surg Oncol. 2018;27(4):688‑94. 
DOI:10.1016/j.suronc.2018.09.004
75. Dusch N, Weiss C, Ströbel P, et al. Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg. 2014;18(4):674‑81. DOI:10.1007/s11605‑013‑2408‑x
76. Zhou W, Wang D, Lou W. Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis. Cancer Control. 2020;27(1):1073274820976593. DOI:10.1177/1073274820976593
77. Sakaguchi T, Valente R, Tanaka K, et al. Surgical treatment of metastatic pancreatic ductal adenocarcinoma: A review of current literature. Pancreatology. 2019;19(5):672‑80. DOI:10.1016/j.pan.2019.05.466
78. Yamada S, Fujii T, Yamamoto T, et al. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. J Gastrointest Oncol. 2021;12(Suppl. 1):S110‑7. DOI:10.21037/jgo‑20‑243
79. Wei M, Shi S, Hua J, et al; Chinese Study Group for Pancreatic Cancer (CSPAC). Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC‑1). BMJ Open. 2019;9(12):e033452. DOI:10.1136/bmjopen‑2019‑033452
80. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27(11):1806‑13. DOI:10.1200/JCO.2008.17.7188
81. Kamisawa T, Isawa T, Koike M, et al. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas. 1995;11(4):345‑9. DOI:10.1097/00006676‑199511000‑00005
82. Mao C, Domenico DR, Kim K, et al. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg. 1995;130(2):125‑34. DOI:10.1001/archsurg.1995.01430020015001
83. Peixoto RD, Speers C, McGahan CE, et al. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med. 2015;4(8):1171‑7. DOI:10.1002/cam4.459
84. NCCN Guidelines. Pancreatic Adenocarcinoma. 2018. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1455. Accessed: 05.10.2023.
85. Fortner JG. Regional resection of cancer of the pancreas: a new surgical approach. Surgery. 1973;73(2):307‑20.
86. Tee MC, Krajewski AC, Groeschl RT, et al. Indications and Perioperative Outcomes for Pancreatectomy with Arterial Resection. J Am Coll Surg. 2018;227(2):255‑69. 
DOI:10.1016/j.jamcollsurg.2018.05.001
87. Boggi U. Resection for pancreatic cancer with arterial involvement: A paradigm shift away from unresectable to „how to do it“. Surgery. 2021;169(5):1036. DOI:10.1016/j.surg.2020.10.047
88. Loos M, Kester T, Klaiber U, et al. Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve. Ann Surg. 2022;275(4):759‑68. DOI:10.1097/SLA.0000000000004054
89. Prakticheskie rekomendatsii po lecheniiu raka podzheludochnoi zhelezy Rossiiskogo obshchestva klinicheskoi onkologii (RUSSCO). 2023. Available at: https://www.rosoncoweb.ru/standarts/RUSSCO/2023/ Accessed: 05.10.2023 (in Russian).
90. Diener MK, Mihaljevic AL, Strobel O, et al. Periarterial divestment in pancreatic cancer surgery. Surgery. 2021;169(5):1019‑25. DOI:10.1016/j.surg.2020.08.030
91. Bachellier P, Addeo P, Faitot F, et al. Pancreatectomy With Arterial Resection for Pancreatic Adenocarcinoma: How Can It Be Done Safely and With Which Outcomes?: A Single Institution’s Experience With 118 Patients. Ann Surg. 2020;271(5):932‑40. DOI:10.1097/SLA.0000000000003010
92. Egorov V, Kim P, Kharazov A, et al. Hemodynamic, Surgical and Oncological Outcomes of 40 Distal Pancreatectomies with Celiac and Left Gastric Arteries Resection (DP CAR) without Arterial Reconstructions and Preoperative Embolization. Cancers (Basel). 2022;14(5):1254. DOI:10.3390/cancers14051254
93. Stoop TF, Ateeb Z, Ghorbani P, et al. Impact of Endocrine and Exocrine Insufficiency on Quality of Life After Total Pancreatectomy. Ann Surg Oncol. 2020;27(2):587‑96. DOI:10.1245/s10434‑019‑07853‑3
94. Wu W, Dodson R, Makary MA, et al. A Contemporary Evaluation of the Cause of Death and Long-Term Quality of Life After Total Pancreatectomy. World J Surg. 2016;40(10):2513‑8. DOI:10.1007/s00268‑016‑3552‑8
95. Téoule P, Tombers K, Rahbari M, et al. Definition und Behandlung der A.-mesenterica-superior-Revaskularisations- und -Dissektions-assoziierten Diarrhö (SMARD-Syndrom) in Deutschland [Definition and treatment of superior mesenteric artery revascularization and dissection-associated diarrhea (SMARD syndrome) (in German)]. Chirurg. 2022;93(2):173‑81. DOI:10.1007/s00104‑021‑01427‑4
96. Sabater L, Ausania F, Bakker OJ, et al. Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery. Ann Surg. 2016;264(6):949‑58. DOI:10.1097/SLA.0000000000001732
97. Roberts KJ, Schrem H, Hodson J, et al. Pancreas exocrine replacement therapy is associated with increased survival following pancreatoduodenectomy for periampullary malignancy. HPB (Oxford). 2017;19(10):859‑67. DOI:10.1016/j.hpb.2017.05.009
98. Kindler HL, Hammel P, Reni M, et al. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022;40(34):3929‑39. DOI:10.1200/JCO.21.01604
99. O’Reilly EM, Melisi D, Macarulla T, et al. Liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18‑month survival rates from the phase 3 NAPOLI 3 trial. J Clin Oncol. 2023;41(Suppl. 16):4006. DOI:10.1200/JCO.2023.41.16_suppl.4006
100. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317‑27. DOI:10.1056/NEJMoa1903387
101. Carrato A, Vieitez JM, Benavides M, et al; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results. Eur J Cancer. 2020;139:51‑8. DOI:10.1016/j.ejca.2020.07.035
102. Neoptolemos JP, Palmer DH, Ghaneh P, et al; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC‑4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011‑24. DOI:10.1016/S0140‑6736(16)32409‑6
103. Conroy T, Hammel P, Hebbar M, et al; Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395‑406. DOI:10.1056/NEJMoa1809775
104. Lee W, Yoon YS, Han HS, et al. Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. World J Surg. 2017;41(2):562‑73. DOI:10.1007/s00268‑016‑3798‑1
105. Cunningham D, Allum WH, Stenning SP, et al; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11‑20. DOI:10.1056/NEJMoa055531
106. Sauer R, Becker H, Hohenberger W, et al; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731‑40. DOI:10.1056/NEJMoa040694
107. Yamada S, Fujii T, Sugimoto H, et al. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas. 2013;42(6):1004‑10. DOI:10.1097/MPA.0b013e31827b2d7c
108. Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018;4(7):963‑69. DOI:10.1001/jamaoncol.2018.0329
109. Wei AC, Ou FS, Shi Q, et al. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019;26(13):4489‑97. DOI:10.1245/s10434‑019‑07685‑1
110. Barbour AP, Samra JS, Haghighi KS, et al; Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators. The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. Ann Surg Oncol. 2020;27(7):2506‑15. DOI:10.1245/s10434‑020‑08205‑2
111. Sohal D, Duong MT, Ahmad SA, et al. SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). J Clin Oncol. 2020;38(Suppl. 15):4504. DOI:10.1200/JCO.2020.38.15_suppl.4504
112. Lutfi W, Talamonti MS, Kantor O, et al. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. Surgery. 2016;160(3):714‑24. DOI:10.1016/j.surg.2016.05.029
113. Versteijne E, Vogel JA, Besselink MG, et al; Dutch Pancreatic Cancer Group. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946‑58. DOI:10.1002/bjs.10870
114. NCCN Guidelines. Pancreatic Adenocarcinoma. Version 2.2022. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1455. Accessed: 21.04.2023.
115. Saito T, Nakai Y, Isayama H, et al. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Pancreas. 2018;47(7):800‑6. DOI:10.1097/MPA.0000000000001079
116. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‑fluorouracil), and high dose radiation + 5‑fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981;48(8):1705‑10. DOI:10.1002/1097‑0142(19811015)48:8<1705:: aid-cncr2820480803>3.0.co;2‑4
117. Group G.T.S. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst. 1988;80(10):751‑5. PMID: 2898536
118. Evans DB, Wolff RA, Hess KR. Adjuvant radiotherapy and 5‑fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 2000;232(5):727. DOI:10.1097/00000658‑200011000‑00028
119. Hammel P, Huguet F, van Laethem JL, et al; LAP07 Trial Group. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844‑53. DOI:10.1001/jama.2016.4324
120. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14(4):317‑26. DOI:10.1016/S1470‑2045(13)70021‑4
121. Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105‑12. DOI:10.1200/JCO.2011.34.8904
122. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000‑01 FFCD/SFRO study. Ann Oncol. 2008;19(9):1592‑9. DOI:10.1093/annonc/mdn281
123. Ren F, Li S, Zhang Y, et al. Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis. Radiat Oncol. 2019;14(1):84. DOI:10.1186/s13014‑019‑1294‑0
124. Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76(1):48‑53. DOI:10.1016/j.radonc.2004.12.022
125. Pollom EL, Alagappan M, von Eyben R, et al. Single-versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Int J Radiat Oncol Biol Phys. 2014;90(4):918‑25. DOI:10.1016/j.ijrobp.2014.06.066
126. Hammer HF. Pancreatic exocrine insufficiency: diagnostic evaluation and replacement therapy with pancreatic enzymes. Dig Dis. 2010;28(2):339‑43. DOI:10.1159/000319411
127. Khronicheskii pankreatit. Klinicheskie rekomendatsii. Obshcherossiiskaia obshchestvennaia organizatsiia «Rossiiskoe obshchestvo khirurgov», Rossiiskaia gastroenterologicheskaia assotsiatsiia, Mezhdunarodnaia obshchestvennaia organizatsiia «Assotsiatsiia khirurgov-gepatologov», Assotsiatsiia «Endoskopicheskoe obshchestvo “REndO”». 2020. Available at: https://cr.minzdrav.gov.ru/schema/273_4. 2020. Accessed: 15.09.2023 (in Russian).
128. Shimizu K, Ito T, Irisawa A, et al. Evidence-based clinical practice guidelines for chronic pancreatitis 2021. J Gastroenterol. 2022;57(10):709‑24. DOI:10.1007/s00535‑022‑01911‑6
129. Working Party of the Australasian Pancreatic Club; Smith RC, Smith SF, Wilson J, et al. Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency. Pancreatology. 2016;16(2):164‑80. DOI:10.1016/j.pan.2015.12.006
130. Kistoznyi fibroz (mukovistsidoz). Klinicheskie rekomendatsii. Soiuz pediatrov Rossii, Assotsiatsiia meditsinskikh genetikov, Rossiiskoe respiratornoe obshchestvo, Rossiiskoe transplantologicheskoe obshchestvo, Assotsiatsiia detskikh vrachei Moskovskoi oblasti. 2021. Rezhim dostupa: https://cr.minzdrav.gov.ru/schema/372_2. 2021. Available at: https://cr.minzdrav.gov.ru/schema/372_2. 2021. Accessed: 15.09.2023 (in Russian).

Л. Г. Жукова¹, Д. С. Бордин*^1–3, Е. А. Дубцова¹, М. А. Ильин^4,5, М. А. Кирюкова¹, П. С. Феоктистова¹, В. И. Егоров<sup>5,6

1</sup>ГБУЗ «Московский клинический научно-практический центр им. А. С. Логинова» Департамента здравоохранения г. Москвы, Москва, Россия;
²ФГБОУ ВО «Российский университет медицины» Минздрава России, Москва, Россия;
³ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России, Тверь, Россия;
⁴ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России, Москва, Россия;
⁵АО «Ильинская больница», Красногорск, Россия;
⁶ФГБУ «Государственный научный центр Российской Федерации – Федеральный медицинский биофизический центр им. А. И. Бурназяна», Москва, Россия
*dbordin@mail.ru

________________________________________________

Liudmila G. Zhukova¹, Dmitry S. Bordin*^1–3, Elena A. Dubtsova¹, Matvey A. Ilin^4,5, Mariia A. Kiriukova¹, Polina S. Feoktistova¹, Vyacheslav I. Egorov<sup>5,6

1</sup>Loginov Moscow Clinical Scientific Center, Moscow, Russia;
²Russian University of Medicine, Moscow, Russia; 
³Tver State Medical University, Tver, Russia;
⁴Russian Scientific Centre of Roentgenoradiology, Moscow, Russia; 
⁵Ilyinsky Hospital JSC, Krasnogorsk, Russia; 
⁶State Research Center – Burnasyan Federal Medical Biophysical Center, Moscow, Russia
*dbordin@mail.ru